Arrowgrass Capital Partners (US)’s Merck MRK Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2019
Q4
Sell
-104,800
Closed -$8.42M 120
2019
Q3
$8.42M Hold
104,800
0.63% 42
2019
Q2
$8.38M Sell
104,800
-282,960
-73% -$21.7M 0.2% 137
2019
Q1
$30.8M Buy
387,760
+282,960
+270% +$21.2M 0.91% 21
2018
Q4
$7.64M Buy
+104,800
New +$7.4M 0.28% 110
2018
Q1
Sell
-65,814
Closed -$3.53M 359
2017
Q4
$3.53M Buy
65,814
+65,156
+9,902% +$3.61M 0.03% 341
2017
Q3
$4.02M Sell
658
-2,304
-78% -$140K 0.03% 390
2017
Q2
$18.1M Buy
2,962
+2,385
+413% +$145K 0.14% 194
2017
Q1
$3.5M Buy
577
+382
+196% +$23.2K 0.04% 367
2016
Q4
$1.09M Sell
195
-687
-78% -$40.2K 0.01% 424
2016
Q3
$5.25M Buy
882
+341
+63% +$19.9K 0.07% 205
2016
Q2
$2.97M Sell
541
-2,280
-81% -$121K 0.03% 244
2016
Q1
$14.2M Buy
2,821
+1,054
+60% +$51.6K 0.17% 94
2015
Q4
$8.9M Buy
1,767
+419
+31% +$21.1K 0.11% 117
2015
Q3
$6.35M Sell
1,348
-3,966
-75% -$211K 0.12% 137
2015
Q2
$28.9M Buy
5,314
+4,622
+668% +$259K 0.43% 45
2015
Q1
$3.79M Sell
692
-21,106
-97% -$1.2M 0.06% 178
2014
Q4
$1.18M Buy
+21,798
New +$1.21M 0.02% 291

Other funds holding MRK

Arrowgrass Capital Partners (US)'s MRK Position: Q1 2018 in Review

Arrowgrass Capital Partners (US) sold out of Merck (MRK) in Q1 2018, closing a stake of 159,612 shares — an estimated $8.57M sold.

Arrowgrass Capital Partners (US) first reported a position in MRK in Q4 2013 and held it in 16 quarters. The position peaked at $15.3M in Q4 2016. 1,992 funds tracked by Wall St. Rank hold MRK as of Q1 2018.

  • Arrowgrass Capital Partners (US) reported no remaining Merck position as of Q1 2018 after selling out during the quarter.
  • Arrowgrass Capital Partners (US) sold 159,612 Merck shares in Q1 2018, an estimated $8.57M.
  • Arrowgrass Capital Partners (US) first reported a position in Merck in Q4 2013 and held it in 16 quarters.
  • Arrowgrass Capital Partners (US)'s Merck position peaked at $15.3M in Q4 2016.
  • 1,992 funds tracked by Wall St. Rank held Merck as of Q1 2018.

Based on Arrowgrass Capital Partners (US)'s 13F filing for Q1 2018, filed 15 May 2018.